Second-line drug therapy for rheumatoid arthritis

New England Journal of Medicine

Volumn 330, Issue 19, 1994, Pages 1368-1375

  Wood, Alastair J j ^a   Cash, Joseph M ^b   Klippel, John H ^c  

^a Cleveland Clinic Foundation ^*

^b LERNER RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTACID AGENT; ANTIMALARIAL AGENT; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FOLIC ACID; FOLINIC ACID; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL TRIAL; DRUG CARCINOGENICITY; DRUG MECHANISM; DRUG MIXTURE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MOUTH ULCER; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SKIN TOXICITY; TERATOGENICITY; THROMBOCYTOPENIA;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY DISEASES; LIVER DISEASES; LUNG DISEASES;

EID: 0028353480     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199405123301908     Document Type: Review

References (117)

1. Keers RY The gold rush 1925-35. Thorax 1980; 35: 884-889
2. Svartz N Salazopyrin, a new sulfanilamide preparation. Acta Med Scand 1942; 110: 577-598
3. Gubner R, August S, Ginsberg V Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176-182
4. Freedman A, Bach F Mepacrine and rheumatoid arthritis. Lancet 1952; 2: 321-321
5. Jaffe IA Comparison of the effect of plasmapheresis and penicillamine on the level of circulating rheumatoid factor. Ann Rheum Dis 1963; 22: 71-76
6. Mason M, Currey HLF, Barnes CG, Dunne JF, Hazleman BL, Strickland ID Azathioprine in rheumatoid arthritis. BMJ 1969; 1: 420-422
7. Jimenez Diaz C Treatment of dysreaction diseases with nitrogen mustards. Ann Rheum Dis 1951; 10: 144-152
8. Yocum DE, Klippel JH, Wilder RL, Cyclosporin A in severe, treatment-refractory rheumatoid arthritis: a randomized study. Ann Intern Med 1988; 109: 863-869
9. Sperling RI, Benincaso AI, Anderson RJ, Coblyn JS, Austen KF, Weinblatt ME Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 1992; 35: 376-384
10. Thomas R, Carroll GJ Reduction of leukocyte and interleukin-1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993; 36: 1244-1252
11. Cronstein BN Molecular mechanism of methotrexate action in inflammation. Inflammation 1992; 16: 411-423
12. Olsen NJ, Murray LM Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989; 32: 378-385
13. Firestein GS, Paine MM, Boyle DL Mechanisms of methotrexate action in rheumatoid arthritis: selective decrease in synovial collagenase gene expression. Arthritis Rheum 1994; 37: 193-200
14. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989; 32: 1065-1073
15. Kremer JM The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1994; 21: 1-5
16. Kahan BD Cyclosporine. N Engl J Med 1989; 321: 1725-1738
17. Sigler JW, Bluhm GB, Duncan H, Sharp JT, Ensign DC, McCrum WR Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Ann Intern Med 1974; 80: 21-26
18. Borg G, Allander E, Lund B, Auranofin improves outcome in early rheumatoid arthritis: results from a 2-year, double blind, placebo controlled study. J Rheumatol 1988; 15: 1747-1754
19. Clark P, Casas E, Tugwell P, Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1993; 119: 1067-1071
20. Hannonen P, Mottonen T, Hakola M, Oka M Sulfasalazine in early rheumatoid arthritis: a 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993; 36: 1501-1509
21. Urowitz MB, Gordon DA, Smythe HA, Pruzanski W, Ogryzio MA Azathioprine in rheumatoid arthritis: a double-blind, cross over study. Arthritis Rheum 1973; 16: 411-418
22. Weinblatt ME, Coblyn JS, Fox DA, Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-822
23. Cooperating Clinics Committee of the American Rheumatism Association. A controlled trial of cyclophosphamide in rheumatoid arthritis. N Engl J Med 1970; 283: 883-889
24. Tugwell P, Bombardier C, Gent M, Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051-1055
25. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1: 1036-1038
26. Lopez-Mendez A, Daniel WW, Reading JC, Ward JR, Alarcon GS Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the Cooperative Systematic Studies of the Rheumatic Diseases Program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 1993; 36: 1364-1369
27. Weinblatt ME, Polisson R, Blotner SD, The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993; 36: 613-619 [Erratum, Arthritis Rheum 1993;36:1028.]
28. Jeurissen MEC, Boerbooms AMT, van de Putte LBA, Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty-eight-week randomized, double-blind trial. Arthritis Rheum 1991; 34: 961-972
29. Jeurissen MEC, Boerbooms AMT, van de Putte LBA, Doersburg WH, Lemmens AM Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis: a randomized, double-blind study. Ann Intern Med 1991; 114: 999-1004
30. Thomas MH, Rothermich NO, Philips VK, Bergen W, Hedrick SW Gold vs D-penicillamine double blind study and followup. J Rheumatol 1984; 11: 764-767
31. Dwosh IL, Stein HB, Urowitz MB, Smythe HA, Hunter T, Ogryzlo MA Azathioprine in early rheumatoid arthritis: comparison with gold and chloroquine. Arthritis Rheum 1977; 20: 685-692
32. Currey HL, Harris J, Mason RM, Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis. BMJ 1974; 3: 763-766
33. Bax DE, Amos RS Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis: a comparison with sodium aurothiomalate. Ann Rheum Dis 1985; 44: 194-198
34. Morassut P, Goldstein R, Cyr M, Karsh J, McKendry RJ Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis — a randomized, double blind 26-week trial. J Rheumatol 1989; 16: 302-306
35. Felson DT, Anderson JJ, Meenan RF The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: result of two metaanalyses. Arthritis Rheum 1990; 33: 1449-1461
36. Felson DT, Anderson JJ, Meenan RF Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum 1990; 33: 140-149
37. Hawley DJ, Wolfe F Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991; 18: 1008-1014
38. Pincus T Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41: 1037-1041
39. Wilske KR, Healey LA Remodeling the pyramid — a concept whose time has come. J Rheumatol 1989; 16: 565-567
40. Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. J Rheumatol 1993; 20: 2005-2009
41. Wolfe F, Hawley DJ, Cathey MA Measurement of gold treatment effect in clinical practice: evidence for effectiveness of intramuscular gold therapy. J Rheumatol 1993; 20: 797-802
42. Epstein WV, Henke CJ, Yelin EH, Katz PP Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis. Ann Intern Med 1991; 114: 437-444
43. Kremer JM, Phelps CT Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992; 35: 138-145
44. Weinblatt ME, Weissman BN, Holdsworth DE, Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum 1992; 35: 129-137
45. Wolfe F, Hawley DJ, Cathey MA Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002
46. Morand EF, McCloud PI, Littlejohn GO Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992; 19: 704-708 [Erratum, J Rheumatol 1992;19:1998.]
47. McKendry RJR, Dale P Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993; 20: 1850-1856
48. Wolfe F, Cathey MA The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991; 18: 1298-1306 [Erratum, J Rheumatol 1991;18:1774.]
49. Sharp JT, Wolfe F, Mitchell DM, Bloch DA The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 1991; 34: 660-668
50. Kushner I, Dawson NV Aggressive therapy does not substantially alter the long-term course of rheumatoid arthritis: so what else is new? Rheum Dis Clin North Am 1993; 19: 163-172
51. Meenan RF, Kazis LE, Anthony JM, Wallin BA The clinical and health status of patients with recent-onset rheumatoid arthritis. Arthritis Rheum 1991; 34: 761-765
52. van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 26-34
53. Tunn EJ, Bacon PA Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993; 32: 97-103
54. Hochberg MC Predicting the prognosis of patients with rheumatoid arthritis: is there a crystal ball? J Rheumatol 1993; 20: 1265-1267
55. Weyand CM, Hicok KC, Conn DL, Goronzy JJ The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992; 117: 801-806
56. Csuka M, Carrera GF, McCarty DJ Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine: a follow-up study. JAMA 1986; 255: 2315-2319
57. Boers M, Ramsden M Long acting drug combinations in rheumatoid arthritis: a formal overview. J Rheumatol 1991; 18: 316-324
58. Porter DR, Capell HA, Hunter J Combination therapy in rheumatoid arthritis — no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol 1993; 20: 645-649
59. Gibson T, Emery P, Armstrong RD, Crisp AJ, Panayi GS Combined d-penicillamine and chloroquine treatment of rheumatoid arthritis — a comparative study. Br J Rheumatol 1987; 26: 279-284
60. Willkens RF, Urowitz MB, Stablein DM, Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992; 35: 849-856
61. Williams HJ, Ward JR, Reading JC, Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992; 35: 259-269
62. Felson DT, Anderson JJ, Meenan RF Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-1125
63. Fries JF, Williams CA, Ramey D, Bloch DA The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36: 297-306
64. Morgan SL, Baggott JE, Vaughn WH, The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 9-18
65. Shiroky JB, Neville C, Esdaile JM, Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993; 36: 795-803
66. Wilkinson SM, Smith AG, Davis MJ, Mattey DL, Dawes PT Suspected cutaneous drug toxicity in rheumatoid arthritis — an evaluation. Br J Rheumatol 1993; 32: 798-803
67. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18: 188-194
68. MacKinnon SK, Starkebaum G, Willkens RF Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1985; 15: 119-126
69. Jeurissen MEC, Boerbooms AMT, van de Putte LBA, Kruijsen MWM Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis. Ann Rheum Dis 1990; 49: 25-27
70. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 1628-1635
71. Zachariae H, Kragballe K, Sogaard H Methotrexate induced liver cirrhosis: studies including serial liver biopsies during continued treatment. Br J Dermatol 1980; 102: 407-412
72. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145-156
73. Kremer JM, Tolman K, Samowitz W Long-term prospective sequential liver biopsies (BXS) in patients with rheumatoid arthritis (RA) on weekly oral methotrexate (MTX). Arthritis Rheum 1990; 33: Suppl: S40-S40 abstract.
74. Aponte J, Petrelli M Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheum 1988; 31: 1457-1464
75. Shergy WJ, Polisson RP, Caldwell DS, Rice JR, Pisetsky DS, Allen NB Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988; 85: 771-774
76. Rau R, Karger T, Herborn G, Frenzel H Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J Rheumatol 1989; 16: 489-493
77. Brick JE, Moreland LW, Al-Kawas F, Chang WWL, Layne RD, DiBartolomeo AG Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin Arthritis Rheum 1989; 19: 31-44
78. Phillips CA, Cera PJ, Mangan TF, Newman ED Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992; 19: 229-233
79. Clegg DO, Furst DE, Tolman KG, Pogue R Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis. J Rheumatol 1989; 16: 1123-1126
80. Whiting-O'Keefe QE, Fye KH, Sack KD Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711-716
81. Walker AM, Funch D, Dreyer NA, Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993; 36: 329-335
82. Zachariae H, Aslam HM, Bjerring P, Sogaard H, Zachariae E, Heickendorff L Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991; 25: 50-53
83. McHenry PM, Bingham EA, Callender ME, Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity. Br J Dermatol 1992; 127: 122-125
84. Verschuur AC, van Everdingen JJ, Cohen EB, Chamuleau RA Liver biopsy versus ultrasound in methotrexate-treated psoriasis: a decision analysis. Int J Dermatol 1992; 31: 404-409
85. Kremer JM, Koff R A debate: should patients with rheumatoid arthritis on methotrexate undergo liver biopsies? Semin Arthritis Rheum 1992; 21: 376-386
86. Kremer JM, Alarcon GS, Lightfoot RW Jr, Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-328
87. Cannon GW Pulmonary complications of antirheumatic drug therapy. Semin Arthritis Rheum 1990; 19: 353-364
88. Hargreaves MR, Mowat AG, Benson MK Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992; 47: 628-633
89. Carroll GJ, Thomas R, Phatouros CC, Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994; 21: 51-54
90. Lang B, Riegel W, Peters T, Peter H-H Low dose methotrexate therapy for rheumatoid arthritis complicated by pancytopenia and Pneumocystis carinii pneumonia. J Rheumatol 1991; 18: 1257-1259
91. Flood DA, Chan CK, Pruzanski W Pneumocystis carinii pneumonia associated with methotrexate therapy in rheumatoid arthritis. J Rheumatol 1991; 18: 1254-1256
92. Law KF, Aranda CP, Smith RL, Berkowitz KA, Ittman MM, Lewis ML Pulmonary cryptococcosis mimicking methotrexate pneumonitis. J Rheumatol 1993; 20: 872-873
93. Croock AD, Furst DE, Helmers RA, Methotrexate does not alter pulmonary function in patients with rheumatoid arthritis. Arthritis Rheum 1989; 32: Suppl: S60-S60 abstract.
94. Smith PJ, Swinburn WR, Swinson DR, Stewart IM Influence of previous gold toxicity on subsequent development of penicillamine toxicity. BMJ 1982; 285: 595-596
95. Sakkas LI, Chikanza IC, Vaughan RW, Welsh KI, Panayi GS Gold induced nephropathy in rheumatoid arthritis and HLA class II genes. Ann Rheum Dis 1993; 52: 300-301
96. Silverberg DS, Kidd EG, Shnitka TK, Ulan RA Gold nephropathy: a clinical and pathologic study. Arthritis Rheum 1970; 13: 812-825
97. Hall CL, Jawad S, Harrison PR, Natural course of penicillamine nephropathy: a long term study of 33 patients. BMJ 1988; 296: 1083-1086
98. Altman RD, Perez GO, Sfakianakis GN Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 1992; 93: 396-402
99. Madhok R, Torley HI, Capell HA A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis. J Rheumatol 1991; 18: 1485-1489
100. Feutren G, Mihatsch MJ Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992; 326: 1654-1660
101. Bradley JD, Brandt KD, Katz BP Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32: 45-53
102. Antonelli MA, Moreland LW, Brick JE Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 1991; 90: 295-298
103. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 1628-1635
104. Laakso M, Mutru O, Isomaki H, Koota K Cancer mortality in patients with rheumatoid arthritis. J Rheumatol 1986; 13: 522-526
105. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA Jr Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case-control follow-up study. Am J Med 1987; 83: 1-9
106. Kinlen LJ Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78: Suppl 1A: 1A-44
107. Bailin PL, Tindall JP, Roenigk HH Jr, Hogan MD Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA 1975; 232: 359-362
108. Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 1992; 19: 1462-1465
109. Kamel OW, van de Rijn M, Weiss LM, Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328: 1317-1321
110. Taillan B, Garnier G, Castanet J, Ferrari E, Pesce A, Dujardin P Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate. Clin Rheumatol 1993; 12: 93-94
111. Penn I, First MR Development and incidence of cancer following cyclosporine therapy. Transplant Proc 1986; 18: Suppl 1: 210-215
112. Kinlen LJ, Sheil AGR, Peto J, Doll R Collaborative UK-Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979; 2: 1461-1466
113. Silman AJ, Petrie J, Hazleman B, Evans SJW Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47: 988-992
114. Zijlmans JMJM, van Rijthoven AWAM, Kluin PM, Jiwa NM, Dijkmans BAC, Kluin-Nelemans JC Epstein-Barr virus-associated lymphoma in a patient with rheumatoid arthritis treated with cyclosporine. N Engl J Med 1992; 326: 1363-1363
115. Cook GC Use of antiprotozoan and anthelmintic drugs during pregnancy: side-effects and contra-indications. J Infect 1992; 25: 1-9
116. Milunsky A, Graef JW, Gaynor MF Jr Methotrexate-induced congenital malformations. J Pediatr 1968; 72: 790-795
117. Kirshon B, Wasserstrum N, Willis R, Herman GE, McCabe ER Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 1988; 72: 462-464